Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/488284a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.
Front Immunol
September 2025
Department of Pathological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States.
Oncolytic virotherapy (OVT) has emerged as a promising and innovative cancer treatment strategy that harnesses engineered viruses to selectively infect, replicate within, and destroys malignant cells while sparing healthy tissues. Beyond direct oncolysis, oncolytic viruses (OVs) exploit tumor-specific metabolic, antiviral, and immunological vulnerabilities to reshape the tumor microenvironment (TME) and initiate systemic antitumor immunity. Despite promising results from preclinical and clinical studies, several barriers, including inefficient intratumoral virus delivery, immune clearance, and tumor heterogeneity, continue to limit the therapeutic advantages of OVT as a standalone modality and hindered its clinical success.
View Article and Find Full Text PDFExploring the effect of copper on the bioactivity of 8-quinolines: an and study.
Dalton Trans
September 2025
Biomedical Inorganic Chemistry Lab, Department of Chemical Sciences, University of Catania, v.le A. Doria 6, 95125, Catania, Italy.
Current anticancer therapy is challenged by the adaptability and resistance of tumor cells as well as limited drug selectivity that causes severe side effects. The scientific community maintains high interest in metal-based chemotherapeutic agents due to their unique interactions with cancer cells, potentially overcoming resistance mechanisms and exploiting the physiopathology of the tumour tissues. Copper, in particular, plays a dual role in cancer, both facilitating tumor progression and triggering cuproptosis, a copper-induced cell death mechanism.
View Article and Find Full Text PDFThe molecular blueprint of targeted radionuclide therapy.
Nat Rev Clin Oncol
September 2025
German Cancer Consortium (DKTK), Partner Site Essen, Essen, Germany.
Targeted radionuclide therapy (TRT) is a cutting-edge treatment approach in oncology that combines the molecular precision of targeted agents with the effect of radiotherapy to selectively deliver cytotoxic radiation to cancer cells. Research efforts from the past few decades have led to a diverse molecular landscape of TRT and have provided lessons for further rational development of targeted radiopharmaceuticals and expansion of the clinical applications of this treatment modality. In this Review, we discuss TRT in the context of therapeutic approaches currently available in oncology, describe the broad range of established and emerging targets for TRT including innovative approaches to exploit vulnerabilities presented by the tumour microenvironment, and address the challenges for clinical translation and molecular optimization.
View Article and Find Full Text PDFNPY-functionalized niosomes for targeted delivery of margatoxin in breast cancer therapy.
Med Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFA Diselenide-Based Triple-Responsive Nanogel for Tumor Chemo-Photoimmunotherapy.
ACS Appl Mater Interfaces
September 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, People's Republic of China.
In this study, we successfully developed a diselenide-based, triple-responsive intelligent nanogel, IR780@BEAP, for lung cancer therapy. Exploiting the elevated levels of reactive oxygen species (ROS) and glutathione (GSH) in the tumor microenvironment (TME), a ROS/GSH dual-responsive diselenide cross-linker (DSe5) was synthesized and used to cross-link betulin (BE) with polysaccharide (AP) while coloading the photosensitizer IR780. The resulting nanogel, IR780@BEAP, exhibited an appropriate particle size (137.
View Article and Find Full Text PDF